Figure 2: Reduced increase in P-Erk1/2 levels in KrasC118S/C118S MEFs upon expressing activated eNOS.
From: Decreased tumorigenesis in mice with a Kras point mutation at C118
(a) Immunoblot of HA-tagged ectopic eNOS, endogenous Kras and tubulin, as well as total (T) and phosphorylated (P) Erk1/2 from two Kras+/+ and two KrasC118S/C118S SV40-immortalized MEF cell lines in the absence or presence of HA-eNOSS1177D. Bottom: mean±s.e.m. of the indicated fold increase in P-Erk1/2 (normalized to T-Erk1/2) from immunoblot analysis of lysates derived seven independent times. (b) Mean±s.e.m. fold increase in P-Erk1/2 levels (normalized to T-Erk1/2) upon expression of eNOSS1177D from lysates derived seven independent times from the two Kras+/+ (+/+) or two KrasC118S/C118S (C118S/C118S) SV40-immortalized MEF cell lines. *P<0.05, as determined by two-tailed unpaired Student’s t-test.
